论文部分内容阅读
目的:通过观察不同抗凝方法在血液透析中的应用效果,为肾衰患者血液透析提供更优选择。方法:将69例慢性肾衰竭患者随机分为3组,标准剂量肝素组首剂给予肝素50-100U/Kg,,并且在随后的治疗过程中,每小时追加首剂使用的剂量,超小剂量肝素组一直持续注入肝素50-100U/Kg,低分子肝素钙组只给予首剂剂量,不追加。结果:对三组的透析器和凝血情况进行比较,在穿刺点压迫时间以及出血情况,以及透析前后APTT和TT等方面进行比较,得出标准剂量组穿刺点压迫时间比其他两组时间长,在出血发生率也比其他两组高,APTT、TT也大于其他两组。结论:在面对具有出血倾向的肾衰竭透析患者,适宜采用小剂量肝素治疗方法,应用低分子肝素,血小板减少发生频率明显降低。低分子肝素对体内外血栓、动静脉血栓形成有较强的抑制作用。
Objective: To observe the effect of different anticoagulation methods in hemodialysis and provide a better choice for hemodialysis patients with renal failure. Methods: Sixty-nine patients with chronic renal failure were randomly divided into three groups. The standard dose heparin group was given the first dose of heparin 50-100U / Kg, and during the subsequent treatment, the dose of the first dose was added every hour. The ultra- Heparin group has been continuously injected heparin 50-100U / Kg, low molecular weight heparin group only given the first dose, do not append. Results: Comparing the dialyzer and coagulation status of the three groups, comparing the time of oppression and bleeding, the APTT and TT before and after dialysis, we found that the puncture time of the standard dose group was longer than that of the other two groups, The bleeding rate was also higher than the other two groups, APTT, TT is also greater than the other two groups. Conclusion: In the face of hemodialysis renal failure patients with bleeding tendency, suitable for low-dose heparin therapy, the application of low molecular weight heparin, thrombocytopenia frequency was significantly lower. Low molecular weight heparin in vivo thrombosis, arteriovenous thrombosis have a strong inhibitory effect.